Omozojie Paul Aigbogun

Dr. Omozojie Paul Aigbogun

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
Omozojie Paul AigbogunOmozojie Paul Aigbogun
Omozojie Paul Aigbogun

3 August 2022 in Xenobiotica
Verified
Journal Article
Open access
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
Omozojie Paul AigbogunOmozojie Paul Aigbogun
Omozojie Paul Aigbogun
Although liquid chromatography-tandem mass spectrometry is the gold standard analytical platform for the quantification of drugs, metabolites, and biomarkers in biological samples, it cannot locali...

30 June 2021 in Xenobiotica
Verified
Journal Article
Closed access
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
Omozojie Paul AigbogunOmozojie Paul Aigbogun
Omozojie Paul Aigbogun
KAKevin J.H Allen
Kevin J.H Allen
MOMadeline N. Owens
Madeline N. Owens
JLJeremy S. Lee
Jeremy S. Lee
EKEd Krol
Ed Krol
A challenge in the development of novel 18F-labelled positron emission tomography (PET) imaging probes is identification of metabolically stable sites to incorporate the 18F radioisotope. Metabolic...

25 January 2023 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Omozojie Paul AigbogunOmozojie Paul Aigbogun
Omozojie Paul Aigbogun
CPChristopher P. Phenix
Christopher P. Phenix
EKEd Krol
Ed Krol
EPEric W. Price
Eric W. Price

Verified
Journal Article
Open access
PDF file
EJElisabet Jakova
Elisabet Jakova
Omozojie Paul AigbogunOmozojie Paul Aigbogun
Omozojie Paul Aigbogun
MMMohamed Taha Moutaoufik
Mohamed Taha Moutaoufik
KAKevin Allen
Kevin Allen
OMOmer Munir
Omer Munir
Francisco Sandoval CayabyabFrancisco Sandoval Cayabyab
Francisco Sandoval Cayabyab
We previously found that chronic adenosine A1 receptor stimulation with N6-Cyclopentyladenosine increased α-synuclein misfolding and neurodegeneration in a novel α-synucleinopathy model, a hallmark of Parkinson’s disease. Here, we aimed to synthesize a dimer caffeine-indan linked by a 6-carbon chain to cross the blood–brain barrier and tested its ability to bind α-synuclein, reducing misfolding, behavioral abnormalities, and neurodegeneration in our rodent model. Behavioral tests and histological stains assessed neuroprotective effects of the dimer compound. A rapid synthesis of the 18F-labeled analogue enabled Positron Emission Tomography and Computed Tomography imaging for biodistribution measurement. Molecular docking analysis showed that the dimer binds to α-synuclein N- and C-termini and the non-amyloid-β-component (NAC) domain, similar to 1-aminoindan, and this binding promotes a neuroprotective α-synuclein “loop” conformation. The dimer also binds to the orthosteric binding site for adenosine within the adenosine A1 receptor. Immunohistochemistry and confocal imaging showed the dimer abolished α-synuclein upregulation and aggregation in the substantia nigra and hippocampus, and the dimer mitigated cognitive deficits, anxiety, despair, and motor abnormalities. The 18F-labeled dimer remained stable post-injection and distributed in various organs, notably in the brain, suggesting its potential as a Positron Emission Tomography tracer for α-synuclein and adenosine A1 receptor in Parkinson’s disease therapy.

3 August 2022 in Xenobiotica
Verified
Journal Article
Closed access
Omozojie Paul AigbogunOmozojie Paul Aigbogun
Omozojie Paul Aigbogun
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
MOMadeline N. Owens
Madeline N. Owens
KAKevin J. H. Allen
Kevin J. H. Allen
JLJeremy S. Lee
Jeremy S. Lee
EKEd Krol
Ed Krol
Aggregates of the protein α-synuclein are associated with pathophysiology of Parkinson’s disease and are present in Lewy Bodies found in the brains of Parkinson’s patients. We previously demonstrated that bifunctional compounds composed of caffeine linked via a 6 carbon chain to either 1-aminoindan (C8-6-I) or nicotine (C8-6-N) bind α-synuclein and protect yeast cells from α-synuclein mediated toxicity. A critical step in development of Positron Emission Tomography (PET) probes for neurodegenerative diseases is evaluation of their metabolic stability. We determined that C8-6-I, and C8-6-N both undergo phase 1 P450 metabolism in mouse, rat, and human liver microsomes. We utilized this metabolic information to guide the design of fluorinated analogs for use as PET probes and determined that the fluorine in 19F-C8-6-I and 19F-C8-6-N is stable to P450 enzymes. We have developed and validated an analytical HPLC-UV method following FDA and EMA guidelines to measure in vitro Phase 1 kinetics of these compounds and determine their Vmax, KM and CLint,u in mouse liver microsomes. We found that C8-6-I and 19F-C8-6-I have a 2 - 4 fold lower CLint,u than C8-6-N, and 19F-C8-6-N. Our approach shows a simple, specific, and effective step by step system to design and develop compounds as PET probes.